MarketCap
Facebook
X
TelegramФармсинтез Gewinn / Verlust 2007-2026 | LIFE
Gewinn / Verlust Jährlich Фармсинтез
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
380 M | 438 M | 372 M | 291 M | 282 M | 724 M | 661 M | 331 M | 378 M | 245 M | 266 M | 412 M | 275 M | 228 M | 180 M | 173 M |
Cost Of Revenue |
299 M | 277 M | 212 M | 262 M | 251 M | 414 M | 271 M | 168 M | 165 M | 155 M | 147 M | 295 M | 170 M | 155 M | 100 M | 93.5 M |
Gross Profit |
80.8 M | 161 M | 160 M | 28.7 M | 31.2 M | 309 M | 390 M | 163 M | 213 M | 90.3 M | 119 M | 117 M | 106 M | 73.8 M | 79.7 M | 79 M |
Gross Profit Ratio |
0.21 | 0.37 | 0.43 | 0.1 | 0.11 | 0.43 | 0.59 | 0.49 | 0.56 | 0.37 | 0.45 | 0.28 | 0.38 | 0.32 | 0.44 | 0.46 |
General and Administrative Expenses |
19.9 M | 33.8 M | 24.1 M | 158 M | 15.5 M | 306 M | 138 M | 50.7 M | 56.7 M | 41.2 M | - | - | 33.3 M | 31.4 M | 30.1 M | 23.2 M |
Selling And Marketing Expenses |
23.8 M | 53.5 M | 43.9 M | 71.9 M | 19.5 M | 39.1 M | 28 M | 32.6 M | 55.3 M | 18 M | - | 52 M | 30.5 M | 26 M | 28.6 M | 23.5 M |
Selling General And Administrative Expenses |
43.7 M | 87.2 M | 68 M | 246 M | 35 M | 345 M | 166 M | 83.3 M | 112 M | 59.2 M | 144 M | 52 M | 63.7 M | 57.5 M | 58.8 M | 46.7 M |
Other Expenses |
188 M | 189 M | 86.8 M | 1.8 B | -43.4 M | 655 M | 445 M | 434 M | 202 M | 204 M | 16.5 M | -88 M | -13.8 M | -7.13 M | -13.7 M | -7.46 M |
Operating Expenses |
248 M | 330 M | 201 M | 2.05 B | -35.5 M | 1.27 B | 968 M | 711 M | 421 M | 280 M | 301 M | 114 M | 63.7 M | 57.5 M | 58.8 M | 46.7 M |
Cost And Expenses |
547 M | 607 M | 413 M | 2.31 B | 215 M | 1.68 B | 1.24 B | 879 M | 586 M | 435 M | -448 M | 409 M | 233 M | 212 M | 159 M | 140 M |
Interest Expense |
41.3 M | 36.4 M | 29.6 M | - | 5.8 M | 4.54 M | 3.17 M | 2.15 M | 2.12 M | 1.86 M | 4.84 M | 3 M | 1.27 M | 3.03 M | 1.63 M | 139 K |
Depreciation And Amortization |
27.5 M | 32 M | 44.4 M | 25.9 M | 54.6 M | 42.6 M | 71.9 M | 31.7 M | 36.2 M | 22.9 M | 27.3 M | 28 M | -13.6 M | -7.13 M | -13.7 M | -7.46 M |
EBITDA |
-140 M | -647 M | -199 M | -192 M | -213 M | -1.01 B | -613 M | -364 M | -160 M | -119 M | -30 M | 31 M | 28 M | 9.26 M | 7.25 M | 24.9 M |
EBITDA Ratio |
-0.37 | -0.73 | -0.98 | -0.66 | 0.13 | -3.81 | -0.8 | -1.57 | -0.42 | -0.52 | -0.11 | 0.08 | 0.1 | 0.04 | 0.04 | 0.14 |
Operating Income |
-167 M | -169 M | -41.4 M | -2.02 B | 66.7 M | -2.88 B | -616 M | -600 M | -208 M | -180 M | -182 M | 3 M | 42 M | 16.4 M | 21 M | 32.3 M |
Operating Income Ratio |
-0.44 | -0.39 | -0.11 | -6.94 | 0.24 | -3.98 | -0.93 | -1.81 | -0.55 | -0.73 | -0.68 | 0.01 | 0.15 | 0.07 | 0.12 | 0.19 |
Income Before Tax |
-209 M | -733 M | -527 M | -2.03 B | 1.81 M | -2.84 B | -945 M | -398 M | -199 M | -153 M | -62.2 M | 28 M | 27 M | 6.23 M | 5.61 M | 24.7 M |
Income Before Tax Ratio |
-0.55 | -1.67 | -1.42 | -6.97 K | 0.01 | -3.93 | -1.43 | -1.2 | -0.53 | -0.63 | -0.23 | 0.07 | 0.1 | 0.03 | 0.03 | 0.14 |
Income Tax Expense |
-1.22 M | -35.9 M | -2.4 M | 217 M | -58 M | -71.3 M | -34.7 M | -43.5 M | 6.02 M | -6.08 M | -7.65 M | 14 M | 7.98 M | -7.82 M | 3.49 M | 7.87 M |
Net Income Ratio |
-0.55 | -1.59 | -1.41 | -6.22 | 0.21 | -3.49 | -1.36 | -1.07 | -0.54 | -0.6 | -0.2 | 0.03 | 0.07 | 0.06 | 0.01 | 0.1 |
Earnings Per Share, EPS |
-0.69 | -2.32 | -1.74 | -6.02 | 0.21 | -9.13 | -5.92 | -2.34 | -1.43 | -1.37 | -0.77 | 0.05 | 0.06 | 0.11 | 0.02 | 0.14 |
EPS Diluted |
-0.69 | -2.32 | -1.74 | -6.02 | 0.2 | -9.13 | -5.92 | -2.34 | -1.43 | -1.37 | -0.77 | 0.05 | 0.06 | 0.11 | 0.02 | 0.14 |
Weighted Average Shares Outstanding |
301 M | 301 M | 301 M | 301 M | 289 M | 276 M | 152 M | 152 M | 143 M | 108 M | 70.7 M | 301 M | 301 M | 125 M | 125 M | 125 M |
Alle Zahlen in RUB-Währung
Gewinn / Verlust Vierteljährlich Фармсинтез
| 2023-Q2 | 2022-Q4 | 2022-Q2 | 2021-Q4 | 2021-Q2 | 2020-Q4 | 2020-Q2 | 2019-Q4 | 2019-Q2 | 2018-Q4 | 2018-Q2 | 2017-Q4 | 2017-Q2 | 2016-Q4 | 2016-Q2 | 2015-Q4 | 2015-Q2 | 2014-Q4 | 2014-Q2 | 2013-Q4 | 2013-Q2 | 2012-Q4 | 2011-Q4 | 2011-Q2 | 2010-Q4 | 2010-Q2 | 2009-Q4 | 2009-Q2 | 2008-Q4 | 2008-Q2 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
172 M | 172 M | 208 M | 216 M | 222 M | 229 M | 142 M | 94.3 M | 197 M | 245 M | 104 M | 380 M | 343 M | 468 M | 193 M | 125 M | 247 M | 189 M | 189 M | 260 M | 46.8 M | 133 M | 206 M | 206 M | 138 M | 138 M | 114 M | 114 M | 90 M | 90 M |
Cost Of Revenue |
119 M | 151 M | 148 M | 166 M | 111 M | 133 M | 78.7 M | 147 M | 115 M | 126 M | 138 M | 120 M | 328 M | 15.9 M | 249 M | 155 M | 293 M | 82.5 M | 82.5 M | 237 M | 32.8 M | 73.7 M | 148 M | 148 M | 84.8 M | 84.8 M | 77.3 M | 77.3 M | 50.1 M | 50.1 M |
Gross Profit |
53.5 M | 20.5 M | 60.3 M | 50.5 M | 111 M | 96.4 M | 63.5 M | -52.7 M | 81.4 M | 119 M | -33.6 M | 260 M | 15.3 M | 453 M | -56.5 M | -30 M | -46.6 M | 106 M | 106 M | 22.4 M | 14 M | 59.5 M | 58.5 M | 58.5 M | 52.8 M | 52.8 M | 36.9 M | 36.9 M | 39.9 M | 39.9 M |
Gross Profit Ratio |
0.31 | 0.119 | 0.29 | 0.233 | 0.498 | 0.42 | 0.447 | -0.559 | 0.414 | 0.486 | -0.323 | 0.684 | 0.045 | 0.966 | -0.293 | -0.241 | -0.189 | 0.563 | 0.563 | 0.086 | 0.299 | 0.447 | 0.284 | 0.284 | 0.384 | 0.384 | 0.323 | 0.323 | 0.443 | 0.443 |
General and Administrative Expenses |
90.5 M | 69.5 M | 41.9 M | 41.9 M | 43.7 M | 46.1 M | 39 M | 55.4 M | 103 M | 118 M | 106 M | 243 M | 331 M | 271 M | 67.3 M | 77.8 M | 84.9 M | 28.3 M | 28.3 M | 106 M | 21.4 M | - | - | - | 16.6 M | 16.6 M | 15.7 M | 15.7 M | 15.1 M | 15.1 M |
Selling And Marketing Expenses |
7.81 M | 15.9 M | 11 M | 29.2 M | 10.9 M | 20.3 M | 18.7 M | 18.4 M | 53.5 M | 61.8 M | 98.8 M | 154 M | 55.3 M | 56.6 M | 47.5 M | 72.5 M | 94.8 M | 27.6 M | 27.6 M | 43.3 M | 15.2 M | - | 26 M | 26 M | 15.2 M | 15.2 M | 13 M | 13 M | 14.3 M | 14.3 M |
Selling General And Administrative Expenses |
98.3 M | 89.4 M | 106 M | 102 M | 319 M | 142 M | 115 M | 89.6 M | 156 M | 200 M | 205 M | 423 M | 386 M | 345 M | 115 M | 170 M | 180 M | 56 M | 56 M | 156 M | 39.9 M | 72 M | 26 M | 26 M | 31.9 M | 31.9 M | 28.7 M | 28.7 M | 29.4 M | 29.4 M |
Other Expenses |
69 M | - | -805 K | -11.7 M | -2.04 M | - | - | 1.76 B | 35.7 M | - | - | - | - | - | - | - | - | 101 M | 101 M | - | - | 8.27 M | -44 M | -44 M | -6.92 M | -6.92 M | -3.56 M | -3.56 M | -6.85 M | -6.85 M |
Operating Expenses |
178 M | 162 M | 126 M | 165 M | 324 M | 178 M | 125 M | 1.85 B | 195 M | 265 M | 362 M | 2.63 B | 483 M | 1.88 B | 784 M | 100 M | 234 M | 211 M | 211 M | 115 M | 173 M | 151 M | 57 M | 57 M | 31.9 M | 31.9 M | 28.7 M | 28.7 M | 29.4 M | 29.4 M |
Cost And Expenses |
297 M | 314 M | 273 M | 331 M | 435 M | 311 M | 204 M | 2 B | 311 M | 391 M | 500 M | 2.75 B | 811 M | 1.9 B | 1.03 B | 255 M | 528 M | 293 M | 293 M | 352 M | 205 M | -224 M | 204 M | 204 M | 117 M | 117 M | 106 M | 106 M | 79.5 M | 79.5 M |
Interest Expense |
- | - | 19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06 M | 1.06 M | - | - | 2.42 M | 1.5 M | 1.5 M | 634 K | 634 K | 1.52 M | 1.52 M | 817 K | 817 K |
Depreciation And Amortization |
8.23 M | 8.18 M | 11.7 M | 15.9 M | 16 M | 26.3 M | 18.1 M | 419 K | 25.5 M | 27 M | 27.6 M | 21.7 M | 29 M | 34.1 M | 37.8 M | 15.5 M | 16.2 M | 18.1 M | 18.1 M | 20.8 M | 6.76 M | 13.7 M | 14 M | 14 M | -6.82 M | -6.82 M | -3.56 M | -3.56 M | -6.85 M | -6.85 M |
EBITDA |
-38.4 M | -59.3 M | -3.73 M | -442 M | -228 M | -307 M | -90.2 M | -160 M | -32.1 M | 786 M | -1.01 B | -2.59 B | -873 M | -2.62 B | -267 M | -253 M | -265 M | -80.2 M | -80.2 M | -115 M | -22.7 M | -15 M | 15.5 M | 15.5 M | 14 M | 14 M | 4.63 M | 4.63 M | 3.62 M | 3.62 M |
EBITDA Ratio |
-0.223 | -0.345 | -0.258 | -0.457 | -0.888 | -0.241 | -0.305 | -1.69 | -0.163 | 0.354 | -2.11 | -1.38 | -1.28 | -2.73 | 3.97 | -2.03 | -1.07 | -0.425 | -0.425 | -0.444 | -0.486 | -0.113 | 0.075 | 0.075 | 0.102 | 0.102 | 0.041 | 0.041 | 0.04 | 0.04 |
Operating Income |
-125 M | -67.5 M | -65.4 M | -115 M | -213 M | -81.5 M | -61.5 M | -1.91 B | -114 M | 59.9 M | -247 M | -547 M | -468 M | -1.31 B | 727 M | -268 M | -281 M | -104 M | -104 M | -136 M | -29.5 M | -91 M | 1.5 M | 1.5 M | 21 M | 21 M | 8.19 M | 8.19 M | 10.5 M | 10.5 M |
Operating Income Ratio |
-0.723 | -0.393 | -0.315 | -0.531 | -0.96 | -0.355 | -0.433 | -20.2 | -0.578 | 0.244 | -2.37 | -1.44 | -1.36 | -2.8 | 3.77 | -2.16 | -1.14 | -0.551 | -0.551 | -0.525 | -0.63 | -0.683 | 0.007 | 0.007 | 0.152 | 0.152 | 0.072 | 0.072 | 0.116 | 0.116 |
Income Before Tax |
-142 M | -164 M | -34.4 M | -454 M | -262 M | -351 M | -120 M | -1.91 B | -117 M | -41.7 M | -509 M | -1.32 B | -1.52 B | -1.18 B | 488 M | -119 M | -279 M | -99.4 M | -99.4 M | 154 M | -154 M | -31.1 M | 14 M | 14 M | 13.5 M | 13.5 M | 3.11 M | 3.11 M | 2.81 M | 2.81 M |
Income Before Tax Ratio |
-0.822 | -0.956 | -0.165 | -2.1 | -1.18 | -1.53 | -0.843 | -20.3 K | -593 | -0.17 | -4.89 | -3.47 | -4.44 | -2.52 | 2.53 | -0.96 | -1.13 | -0.526 | -0.526 | 0.592 | -3.28 | -0.233 | 0.068 | 0.068 | 0.098 | 0.098 | 0.027 | 0.027 | 0.031 | 0.031 |
Income Tax Expense |
21.8 M | 24.1 M | 22.9 M | -17.1 M | -18.8 M | 20.6 M | -23 M | 141 M | 76.1 M | 10.2 M | 123 M | 53.5 M | 17.8 M | 12.4 M | 24 M | 47.7 M | 4.16 M | 3.01 M | 3.01 M | 1.66 M | 2.21 M | -3.82 M | 7 M | 7 M | 3.99 M | 3.99 M | -3.91 M | -3.91 M | 1.74 M | 1.74 M |
Net Income Ratio |
-0.949 | -0.816 | -0.324 | -2.06 | -1.14 | -1.82 | -0.756 | -18.8 | -0.206 | -0.128 | -3.71 | -2.67 | -4.39 | -2.46 | 2.66 | -0.577 | -1.15 | -0.542 | -0.542 | 0.598 | -3.23 | -0.205 | 0.034 | 0.034 | 0.069 | 0.069 | 0.061 | 0.061 | 0.012 | 0.012 |
Earnings Per Share, EPS |
-0.54 | -0.48 | -0.22 | -1.48 | -0.84 | -1.39 | -0.36 | -6.1 | -0.13 | -0.107 | -1.28 | -4.04 | -5 | -7.6 | 3.38 | -0.48 | -1.88 | -0.715 | -0.715 | 1.26 | -1.64 | -0.38 | 0.023 | 0.023 | 0.032 | 0.032 | 0.055 | 0.055 | 0.009 | 0.009 |
EPS Diluted |
-0.54 | -0.48 | -0.22 | -1.48 | -0.84 | -1.39 | -0.36 | -6.1 | -0.13 | -0.105 | -1.28 | -4.04 | -5 | -7.6 | 3.38 | -0.48 | -1.88 | -0.715 | -0.715 | 1.26 | -1.64 | -0.38 | 0.023 | 0.023 | 0.032 | 0.032 | 0.055 | 0.055 | 0.009 | 0.009 |
Weighted Average Shares Outstanding |
303 M | 295 M | 301 M | 301 M | 301 M | 301 M | 298 M | 290 M | 312 M | 294 M | 302 M | 251 M | 301 M | 152 M | 152 M | 152 M | 151 M | 143 M | 143 M | 123 M | 92.5 M | 70.7 M | 301 M | 301 M | 301 M | 301 M | 125 M | 125 M | 125 M | 125 M |
Alle Zahlen in RUB-Währung
Die Gewinn- und Verlustrechnung ist einer der drei wichtigsten Finanzberichte eines Unternehmens Фармсинтез (neben der Bilanz und dem Kapitalflussrechnung). Sie zeigt, wie das Unternehmen Geld verdient und welche Ausgaben es hat:
- Wie viel Umsatz das Unternehmen erzielt hat
- Wie viel es für Produktion, Personal, Marketing, Steuern usw. ausgegeben hat
- Welcher Gewinn am Ende übrig geblieben ist
Die Analyse der Gewinn- und Verlustrechnung hilft Investoren zu verstehen, ob das Unternehmen stabile und wachsende Gewinne erzielt, wie effektiv es seine Ausgaben kontrolliert und ob es in der Lage ist, zukünftig Einkommen zu generieren. Außerdem zeigt diese Analyse, wie das Unternehmen mit Krisen und wirtschaftlichen Zyklen umgeht und ermöglicht die Einschätzung des Potenzials für Kurssteigerungen und Dividendenausschüttungen.
Besonderheiten- Die Gewinn- und Verlustrechnung kann sowohl regelmäßige als auch einmalige Posten enthalten (zum Beispiel Gewinne aus dem Verkauf von Vermögenswerten). Für eine korrekte Analyse müssen die Kerndaten von Einmaleffekten getrennt werden.
- Oft veröffentlichen Unternehmen Zwischenberichte (z. B. Quartalsberichte), die eine schnellere Verfolgung der Entwicklung ermöglichen.
- Die gemeinsame Analyse der Gewinn- und Verlustrechnung mit der Bilanz und der Kapitalflussrechnung liefert ein umfassendes Bild der finanziellen Gesundheit des Unternehmens.
USA
Germany
Australia
France
Britain
Danmark
Russia
Canada
Israel
Cayman-islands
